智通财经APP获悉，中国抗体-B(03681)再涨超5%，截至发稿，涨4.62%，报2.04港元，成交额1336.18万港元。
消息面上，中国抗体宣布，其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开放研究》上发表。该研究显示，SM17通过双重抑制Th2/Th17通路及抗纤维化活性，显著改善慢性鼻窦炎伴鼻息肉（CRSwNP）和特发性肺纤维化（IPF）的病理特征，支持其成为变革性疗法的潜力。
中国抗体董事长、执行董事兼首席执行官梁瑞安称，非常高兴公司在《欧洲呼吸杂志子刊-开放研究》上发表了关于SM17的临床前研究，突显了其治疗CRSwNP和IPF的潜力。这些结果表明SM17是一种极具前景的潜在同类首创生物制剂，靶向关键的上游警报素(IL-25)。通过同时靶向Th2炎症、Th17分化和纤维化，SM17可能为CRSwNP和IPF提供一种多方面的治疗策略，有潜力填补当前针对下游效应器疗法存在局限性的未满足需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.